Zacks Investment Research lowered shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
A number of other equities analysts also recently commented on ASMB. William Blair reissued an outperform rating on shares of Assembly Biosciences in a research note on Friday, May 10th. BidaskClub downgraded shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a research note on Monday, June 24th. Finally, Chardan Capital reissued a hold rating on shares of Assembly Biosciences in a research note on Sunday, June 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $41.20.
NASDAQ:ASMB traded down $0.38 during trading hours on Wednesday, reaching $13.20. The company’s stock had a trading volume of 446,900 shares, compared to its average volume of 288,611. The stock has a market cap of $352.08 million, a P/E ratio of -3.32 and a beta of 1.46. Assembly Biosciences has a 12 month low of $12.75 and a 12 month high of $44.65. The company has a quick ratio of 7.97, a current ratio of 7.97 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $14.39.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.01. The company had revenue of $3.89 million during the quarter, compared to the consensus estimate of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. On average, analysts expect that Assembly Biosciences will post -4.34 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Assembly Biosciences by 3.4% in the fourth quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock worth $43,193,000 after purchasing an additional 63,554 shares during the last quarter. RTW Investments LP purchased a new position in Assembly Biosciences in the fourth quarter worth $15,532,000. Victory Capital Management Inc. grew its holdings in Assembly Biosciences by 5.9% in the first quarter. Victory Capital Management Inc. now owns 562,399 shares of the biopharmaceutical company’s stock worth $11,074,000 after purchasing an additional 31,490 shares during the last quarter. Emerald Advisers LLC grew its holdings in Assembly Biosciences by 20.3% in the first quarter. Emerald Advisers LLC now owns 468,379 shares of the biopharmaceutical company’s stock worth $9,222,000 after purchasing an additional 79,039 shares during the last quarter. Finally, FMR LLC grew its holdings in Assembly Biosciences by 0.6% in the first quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock worth $8,776,000 after purchasing an additional 2,680 shares during the last quarter. 86.44% of the stock is currently owned by institutional investors and hedge funds.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Read More: What are municipal bonds?
Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.